Clinical trials: Early-stage Breast Cancer
TNBC, TNBC - Triple-Negative Breast Cancer
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative breast cancer.
- Conditions
- TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
- Trial name
- NCT07017673
- Testing
- Ivonescimab, Carboplatin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Cedars-Sinai Medical Center
Breast Cancer, Early-stage Breast Cancer
SABER Study for Selected Early Stage Breast Cancer
The purpose of this study is to find the most effective dose of radiation therapy to give to breast tumors in a shorter period of time, prior to standard partial mastectomy/axillary surgery.
- Trial name
- SABER (NCT04360330)
- Testing
- Stereotactic Ablative Breast Radiotherapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Miami
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement.
- Conditions
- Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Breast Carcinoma
- Trial name
- PROFFi (NCT06113016)
- Testing
- Biospecimen Collection, Educational Intervention, Exercise Intervention
- Where
- 6 sites in United States
- Volunteers
- 164 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Early-stage or Locally Advanced HER2-positive Breast Cancer
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
This study is a multicenter, randomized, open-label, parallel Phase III clinical trial. 650 early-stage or locally advanced breast cancer participants will be enrolled and randomly assigned to SHR-A1811 monotherapy group (trial…
- Trial name
- NCT07196774
- Testing
- SHR-A1811 for Injection, Docetaxel injection, Trastuzumab Injection
- Where
- 2 sites in China
- Volunteers
- 740 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Early-stage Breast Cancer
Outcomes and Cosmesis With Whole Breast Irradiation and Boost
This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB).
- Trial name
- NCT06295744
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer Female, Early-stage Breast Cancer
IORT-Breast at Medical Center Navicent Health
Intraoperative Breast Radiation Therapy (IORT-Breast) utilizing the Xoft Axxent Electronic Brachytherapy System (Xoft) has been recently introduced as a treatment option for women 50 years of age and older who have early stage…
- Trial name
- IORT-Breast (NCT04595435)
- Testing
- Lumpectomy, Intraoperative Radiation Therapy
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Wake Forest University Health Sciences
Early-stage Breast Cancer, Invasive Ductal Carcinoma of Female Breast
Radiation After No Axillary Nodal Sampling
This is a single arm, pilot, prospective study to evaluate the safety of partial breast irradiation in women who undergo breast conserving surgery without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection…
- Trial name
- RADIANS (NCT07723209)
- Testing
- Partial Breast Irradiation (PBI)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- NYU Langone Health
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer.
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNADalHR (NCT06970912)
- Testing
- Dalpiciclib + Aromatase Inhibitor with ctDNA-Guided Therapy, Taxane-Based Neoadjuvant Chemotherapy
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Peking University People's Hospital
Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
Exploring the dynamics of ctDNA following neoadjuvant therapy with CDK4/6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy
- Conditions
- Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
- Trial name
- DNACDKHR (NCT07366112)
- Testing
- CDK4/6 inhibitor with endocrine therapy
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Peking University People's Hospital
Early-stage Breast Cancer
Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment
The main purpose of this study is to evaluate the quality of life of premenopausal participants with Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor-2 (HER2) negative breast cancer who are receiving, in…
- Trial name
- ROSE (NCT05377684)
- Where
- 22 sites in Italy
- Volunteers
- 450 people
- Sponsor
- Ipsen
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed…
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- ACCESS-PC (NCT06834204)
- Testing
- PC2: Primary Care Connect
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Rutgers, The State University of New Jersey
Early-stage Breast Cancer, Obesity
BAriaTric Surgery After Breast Cancer Treatment (BATS)
This is a feasibility study to gain an understanding of the willingness of women with a history of early stage breast cancer and current obesity to enroll in a weight-loss study, accept an assigned intervention (bariatric surgery…
- Trial name
- NCT03946423
- Testing
- Bariatric Surgery with Sleeve Gastrectomy, Lifestyle Intervention
- Sponsor
- Masonic Cancer Center, University of Minnesota
Early-stage Breast Cancer
Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy
The goal of this randomized, pragmatic clinical trial is to evaluate the omission of granulocyte colony-stimulating factors (G-CSF) in breast cancer patients receiving paclitaxel portion of dose-dense adriamycin-cyclophosphamide…
- Trial name
- REaCT-OGF (NCT05753618)
- Testing
- Granulocyte Colony-Stimulating Factor (G-CSF), Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
- Where
- 3 sites in Canada
- Volunteers
- 242 people
- Sponsor
- Ottawa Hospital Research Institute
Early-stage Breast Cancer
Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
REaCT ZOL will compare one 4 mg dose of Zoledronate vs. one 4 mg dose of Zoledronate given every 6 months for 3 years.
- Trial name
- REaCT-ZOL (NCT03664687)
- Testing
- Zoledronate
- Where
- 6 sites in Canada
- Volunteers
- 211 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer, Early-stage Breast Cancer
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
In this research study, investigators are testing if a dose-increasing strategy for abemaciclib will have less side effects and be better tolerated than the standard dosage of abemaciclib for participants with early-stage…
- Conditions
- Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Trial name
- NCT06001762
- Testing
- Abemaciclib, Tamoxifen, Anastrozole
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Effects of a Nursing-led Communication Using Mobile Health Information in Breast Cancer Patients Undergoing Concurrent Chemotherapy
Breast cancer is the most common malignant tumor among women. Side effects from initial chemotherapy include sleep disorders, anxiety, depression, and reduced quality of life.
- Trial name
- breast cancer (NCT06949046)
- Testing
- nursing-led communication support, Nursing routine treatment
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Defense Medical Center, Taiwan
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Cancer Exercise: Evaluation of a Mobile App in Breast Cancer Survivors
This study will examine whether a mobile app increases exercise levels in breast cancer survivors after treatments, reduces fatigue, and improves physical functions.
- Trial name
- NCT06791018
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 132 people
- Sponsor
- University of Alberta
Breast Cancer, Early Stage
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
This trial is designed to determine the feasibility of 1 year of adjuvant enzalutamide, an androgen receptor (AR) antagonist for the treatment of patients with early stage, AR(+) triple negative breast cancer (TNBC).
- Conditions
- Breast Cancer, Early Stage, Triple Negative Breast Cancer
- Trial name
- NCT02750358
- Testing
- Enzalutamide, assessment
- Where
- 12 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Invasive, Early-stage Breast Cancer
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in…
- Conditions
- Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Trial name
- BRE-04 (NCT04891068)
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois at Chicago
Early Stage Breast Carcinoma, Breast Cancer
Risk-Stratified Hypofractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer
This prospective study is designed to evaluate the feasibility, efficacy, and safety of risk-stratified hypofractionated radiotherapy after breast-conserving surgery in patients with early breast cancer.
- Trial name
- NCT07657442
- Testing
- Whole-breast irradiation and tumor bed boost, Partial-breast irradiation
- Where
- China
- Volunteers
- 649 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences